摘要
目的观察国产替罗非班在急性冠脉综合征(ACS)介入治疗中应用的长期疗效。方法共入选123例ACS患者,其中男69例,女54例,均符合冠脉介入治疗适应证并成功进行了冠脉血运重建。替罗非班按0.4μg.kg-1.min-1静脉滴注,30 min后改为0.1μg.kg-1.min-1,连续静脉滴注24～48 h。术后肝素或低分子肝素减为半量,阿司匹林及氯吡格雷按ACS的常规剂量使用。观察用药后30 d及1年内任何原因的死亡、新的心肌梗死及顽固性心绞痛的发生情况。结果30 d内因颅内出血死亡1例(0.8%),无新的心肌梗死及顽固性心绞痛发生。随访1年内无死亡、新的心肌梗死发生,发生心绞痛2例(1.6%)。发生轻中度出血15例(12.2%),严重出血2例(1.6%)。结论国产替罗非班是一种选择性高、抗血小板疗效好、安全性高的药物,长期随访疗效肯定,适合ACS患者应用。
Objective To observe long-term efficacy of Tirofiban in interventional treatment of patients with Acute Coronary Syndrome（ACS）.Methods One hundred twenty-three ACS patients（69 males,54 females）,who were in line with the current coronary interventional treatment indications and received coronary revascularization successfully,were enrolled and first given intravenous drip of domestic tirofiban in a dose of 0.4 μg·kg^-1.min^-1or 30 min,and then in a dose of 0.1 μg·kg^-1.min^-1ontinuously for 24 h^48 h.Heparin or low-molecular-weight heparin was reduced by half,and aspirin and clopidogrel were given in conventional dose.Death for any reason,new myocardial infarction and refractory angina pectoris were observed within 30 days or 1 year after use of tirofiban.Results Within 30 days of medication,1 patient died of intracranial hemorrhage（0.8%）,no more myocardial infarction and refractory angina pectoris occurred.After a 1-year follow up,no more deaths or myocardial infarctions were noted,but angina pectoris appeared in 2 patents（1.6%）;15 presented with mild-moderate bleeding（12.2%）,2 with severe bleeding.Conclusion Tirofiban,a safer drug with high selectivity and good anti-platelet effectiveness,is fit for ACS patients.
出处
《中国全科医学》
CAS
CSCD
北大核心
2010年第5期535-536,共2页
Chinese General Practice
关键词
盐酸替罗非班
急性冠脉综合征
冠脉介入治疗
长期疗效
Tirofiban
Acute coronary syndrome
Coronary interventional treatment
Long-term efficacy
